Drug Interactions between selumetinib and vadadustat
This report displays the potential drug interactions for the following 2 drugs:
- selumetinib
- vadadustat
Interactions between your drugs
selumetinib vadadustat
Applies to: selumetinib and vadadustat
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with moderate or potent inhibitors of the uptake transporters organic anion transporter 1 and/or 3 (OAT1, OAT3) may increase the plasma concentrations and the risk of adverse effects associated with vadadustat. According to the manufacturer, coadministration with probenecid, a potent OAT1/OAT3 inhibitor, increased systemic exposure (AUC) of vadadustat by almost 2-fold. Increased systemic exposure to vadadustat may result in a rapid rise in hemoglobin and increase the risk of adverse reactions such as thromboembolic events, diarrhea, hypertension, liver injury, seizures, pneumonia, and increased cardiovascular and mortality risk.
MANAGEMENT: Close clinical and laboratory monitoring for adverse effects is advised if vadadustat is used concomitantly with moderate or potent OAT1 and/or OAT3 inhibitors. Additionally, close monitoring of hemoglobin levels is advised following initiation or discontinuation of treatment with moderate or potent OAT1/OAT3 inhibitors, and the vadadustat dosage adjusted as necessary in accordance with the prescribing information.
Drug and food interactions
selumetinib food
Applies to: selumetinib
Grapefruit juice can increase the blood levels of selumetinib. This may increase the risk and/or severity of serious side effects such as diarrhea; colitis (inflammation of the colon); skin rashes; cardiomyopathy (a condition that affects the heart muscle and its ability to pump blood); rhabdomyolysis (a rare condition involving the breakdown of skeletal muscle tissue that can cause kidney damage and death); and eye problems that can lead to blindness. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with selumetinib. Talk to your doctor or pharmacist if you have any questions or concerns. You should seek prompt medical attention if you experience severe diarrhea; severe skin reactions (rash over a large area of the body, peeling skin, blisters); signs and symptoms of heart trouble (persistent coughing or wheezing, shortness of breath, swelling of ankles and feet, fatigue, increased heart rate); muscle problems (unexplained muscle pain, tenderness or weakness, especially with fever and/or dark colored urine); or vision problems (blurred vision, light sensitivity, dark spots or floaters, vision loss). It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
vadadustat food
Applies to: vadadustat
Consumer information for this interaction is not currently available.
MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.
MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.